<p>ABVC BioPharma（纳斯达克代码：ABVC - 获取免费报告）于周三发布了季度财报。该公司报告每股收益为（$0.13），据 Zacks 报道。ABVC BioPharma 的股本回报率为负 29.62%，净利润率为负 963.46%。</p>
<p>获取 <strong>ABVC BioPharma</strong> 的提醒：</p>
<h2>ABVC BioPharma 股价上涨 1.0%</h2>
<p>周三中午交易时，ABVC BioPharma 的股票上涨了$0.03，达到$2.97。该股票交易量为 77,893 股，而其平均交易量为 482,299 股。该公司的市值为 5044 万美元，市盈率为-22.85，贝塔值为 0.27。该公司 50 日简单移动平均线为$2.72，200 日简单移动平均线为$1.52。ABVC BioPharma 的 52 周最低价为$0.40，52 周最高价为$5.48。</p>
<h2>机构投资者对 ABVC BioPharma 的看法</h2>
<p>一家机构投资者最近增加了对 ABVC BioPharma 股票的持仓。根据其最近向证券交易委员会（SEC）提交的文件，Geode Capital Management LLC 在第二季度将其在 ABVC BioPharma, Inc.（纳斯达克代码：ABVC - 免费报告）中的持仓增加了 5.8%。该基金在本季度额外购买了 6,017 股后，持有该公司 110,499 股股票。根据其最近的 SEC 文件，Geode Capital Management LLC 持有的 ABVC BioPharma 股票约占 0.65%，价值 246,000 美元。11.38% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 ABVC BioPharma</h2>
<p>（获取免费报告）</p>
<p>ABVC BioPharma, Inc 是一家临床阶段的生物制药公司，开发药物和医疗设备以满足美国未满足的医疗需求。该公司正在开发 ABV-1501，目前处于 II 期临床试验中，是一种用于三阴性乳腺癌的联合疗法；ABV-1504 已完成 II 期临床试验，针对重度抑郁症；ABV-1505 目前处于 II 期临床试验中，针对成人注意力缺陷多动障碍；ABV-1703 目前处于 II 期临床试验中，治疗转移性胰腺癌；ABV-1702 目前处于 II 期临床试验中，治疗骨髓增生异常综合症；ABV-1601 目前处于 I/II 期临床试验中，治疗癌症患者的抑郁症。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 ABVC BioPharma</li>
<li>宠物是大生意：4 只值得加入您投资组合的大型宠物股票</li>
<li>亚马逊的空头们已举白旗——值得期待</li>
<li>什么是空头头寸？如何使用它</li>
<li>Tempus AI 强劲的第二季度推动增长故事——未来还有更多上升空间？</li>
<li>特殊目的收购公司（SPAC）您需要知道的事项</li>
<li>CAVA 的蜜月以 16% 的股价下跌结束</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWQw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资$1,000 在 ABVC BioPharma 吗？</h2>
<p>在您考虑 ABVC BioPharma 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ABVC BioPharma 并不在名单上。</p>
<p>虽然 ABVC BioPharma 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ABVC

<p>ABVC BioPharma（纳斯达克代码：ABVC）公布了其季度财报，每股亏损为（$0.13）。该公司的股本回报率为负 29.62%，净利润率为 963.46%。股价上涨 1.0%，至$2.97，市值为 5044 万美元。机构投资者持有该股票的 11.38%，Geode Capital Management 将其持仓增加了 5.8%。ABVC BioPharma 正在为多种医疗条件开发几种处于临床试验阶段的药物</p>

<p>ABVC BioPharma (NASDAQ:ABVC - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, Zacks reports. ABVC BioPharma had a negative return on equity of 29.62% and a negative net margin of 963.46%.</p>
<div class="lb-trans"><p>ABVC BioPharma（纳斯达克代码：ABVC - 获取免费报告）于周三发布了季度财报。该公司报告每股收益为（$0.13），据 Zacks 报道。ABVC BioPharma 的股本回报率为负 29.62%，净利润率为负 963.46%。</p>
</div><p>Get <strong>ABVC BioPharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>ABVC BioPharma</strong> 的提醒：</p>
</div><h2>ABVC BioPharma Trading Up 1.0%</h2>
<div class="lb-trans"><h2>ABVC BioPharma 股价上涨 1.0%</h2>
</div><p>Shares of ABVC BioPharma stock traded up $0.03 during mid-day trading on Wednesday, reaching $2.97. 77,893 shares of the stock were exchanged, compared to its average volume of 482,299. The company has a market cap of $50.44 million, a price-to-earnings ratio of -22.85 and a beta of 0.27. The firm has a 50-day simple moving average of $2.72 and a 200 day simple moving average of $1.52. ABVC BioPharma has a fifty-two week low of $0.40 and a fifty-two week high of $5.48.</p>
<div class="lb-trans"><p>周三中午交易时，ABVC BioPharma 的股票上涨了$0.03，达到$2.97。该股票交易量为 77,893 股，而其平均交易量为 482,299 股。该公司的市值为 5044 万美元，市盈率为-22.85，贝塔值为 0.27。该公司 50 日简单移动平均线为$2.72，200 日简单移动平均线为$1.52。ABVC BioPharma 的 52 周最低价为$0.40，52 周最高价为$5.48。</p>
</div><h2>Institutional Investors Weigh In On ABVC BioPharma</h2>
<div class="lb-trans"><h2>机构投资者对 ABVC BioPharma 的看法</h2>
</div><p>An institutional investor recently raised its position in ABVC BioPharma stock. Geode Capital Management LLC increased its position in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC - Free Report) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 110,499 shares of the company's stock after acquiring an additional 6,017 shares during the quarter. Geode Capital Management LLC owned about 0.65% of ABVC BioPharma worth $246,000 as of its most recent SEC filing. 11.38% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家机构投资者最近增加了对 ABVC BioPharma 股票的持仓。根据其最近向证券交易委员会（SEC）提交的文件，Geode Capital Management LLC 在第二季度将其在 ABVC BioPharma, Inc.（纳斯达克代码：ABVC - 免费报告）中的持仓增加了 5.8%。该基金在本季度额外购买了 6,017 股后，持有该公司 110,499 股股票。根据其最近的 SEC 文件，Geode Capital Management LLC 持有的 ABVC BioPharma 股票约占 0.65%，价值 246,000 美元。11.38% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About ABVC BioPharma</h2>
<div class="lb-trans"><h2>关于 ABVC BioPharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.</p>
<div class="lb-trans"><p>ABVC BioPharma, Inc 是一家临床阶段的生物制药公司，开发药物和医疗设备以满足美国未满足的医疗需求。该公司正在开发 ABV-1501，目前处于 II 期临床试验中，是一种用于三阴性乳腺癌的联合疗法；ABV-1504 已完成 II 期临床试验，针对重度抑郁症；ABV-1505 目前处于 II 期临床试验中，针对成人注意力缺陷多动障碍；ABV-1703 目前处于 II 期临床试验中，治疗转移性胰腺癌；ABV-1702 目前处于 II 期临床试验中，治疗骨髓增生异常综合症；ABV-1601 目前处于 I/II 期临床试验中，治疗癌症患者的抑郁症。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than ABVC BioPharma</li>
<li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li>
<li>Amazon’s Bears Have Raised the White Flag—Get Excited</li>
<li>What is Short Interest? How to Use It</li>
<li>Tempus AI’s Strong Q2 Fuels Growth Story—More Upside Ahead?</li>
<li>Special Purpose Acquisition Company (SPAC) What You Need to Know</li>
<li>CAVA’s Honeymoon Ends With a 16% Stock Drop</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 ABVC BioPharma</li>
<li>宠物是大生意：4 只值得加入您投资组合的大型宠物股票</li>
<li>亚马逊的空头们已举白旗——值得期待</li>
<li>什么是空头头寸？如何使用它</li>
<li>Tempus AI 强劲的第二季度推动增长故事——未来还有更多上升空间？</li>
<li>特殊目的收购公司（SPAC）您需要知道的事项</li>
<li>CAVA 的蜜月以 16% 的股价下跌结束</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWQw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=ABVC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in ABVC BioPharma Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资$1,000 在 ABVC BioPharma 吗？</h2>
</div><p>Before you consider ABVC BioPharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 ABVC BioPharma 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABVC BioPharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 ABVC BioPharma 并不在名单上。</p>
</div><p>While ABVC BioPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ABVC BioPharma 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

ABVC BioPharma（NASDAQ 代码：ABVC）公布季度财报结果